Dr. Larry Norton is a board-certified medical oncologist specializing in breast cancer. He is currently Senior Vice President of the Office of the President, Founding Medical Director of the Evelyn H. Lauder Breast Center, and Norna S. Sarofim Chair of Clinical Oncology at Memorial Sloan Kettering Cancer Center. His work focuses on optimizing cancer therapy through mathematical modeling, cancer metastasis research, and the development of effective breast cancer treatments including paclitaxel and trastuzumab.

Current Position

Senior Vice President, Office of the President, Memorial Sloan Kettering Cancer Center
Founding Medical Director, Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center
Norna S. Sarofim Chair of Clinical Oncology, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
Founder and Scientific Director, Breast Cancer Research Foundation (1993 – Present)

Education

AB with Highest Distinction — University of Rochester
MD — College of Physicians and Surgeons, Columbia University
Residency in Internal Medicine — Albert Einstein College of Medicine / Bronx Municipal Hospital Center
Fellowship in Medical Oncology — National Cancer Institute

Professional Experience

Senior Vice President of the Office of the President at Memorial Sloan Kettering Cancer Center, where he cares for women with breast cancer in his clinical practice.
Founding Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center.
Founder and Scientific Director of the Breast Cancer Research Foundation since its inception in 1993.
Professor of Medicine at Weill Cornell Medical College.
U.S. Presidential appointee to the National Cancer Advisory Board, the board of directors of the National Cancer Institute, where he served as Chair of the Budget Sub-Committee.
Former Director of the American Society of Clinical Oncology, serving as President of ASCO and subsequently Chair of the ASCO Foundation, now the Conquer Cancer Foundation.
Vice-Chair of the Lymphoma Committee and long-serving Chair of the Breast Committee of the Cancer and Leukemia Group B, now the Alliance for Clinical Trials in Oncology.
Served on and chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences.
Editorial board member and reviewer for numerous medical journals, and advisory board member of many advocacy and medical institutions including Cold Spring Harbor Laboratory Cancer Center and several Specialized Programs of Research Excellence.
Principal Investigator of an NCI Program Project Grant in Models of Human Breast Cancer.
Visiting professor throughout the U.S., Canada, South America, Europe, Israel, and Asia, having trained many cancer physicians and researchers.

Research Activity

Co-inventor of the Norton-Simon Model of cancer growth, which has broadly influenced cancer therapy.
Pioneer of the self-seeding concept of cancer metastasis and growth.
Application of mathematical methods to optimizing dose and schedule in cancer treatment.
Involvement in the development of effective cancer agents including paclitaxel and trastuzumab.
Author of more than 470 published articles and 110 book chapters and reviews

Memberships / Honors / Awards

Castle Connolly: America’s Top Doctor (2023, 2024, 2025, 2026)
Top Doctors New York Metro Area, Castle Connolly (2023)
Elected to the American Academy of Arts & Sciences (2021)
Gianni Bonadonna Award, ASCO, in recognition of distinguished accomplishments in advancing the field of breast cancer (2013)
National Physician of the Year Award, Castle Connolly Medical Ltd. (2010)
David A. Karnofsky Award, ASCO’s highest honor (2004)
McGuire Lecturer, San Antonio Breast Cancer Symposium
Recognition from MD Anderson Cancer Center, the Society for MSKCC, the Italian American Foundation for Cancer Research, the Don Shula Foundation, SHARE (NY), the Susan G.
Komen Foundation, and The Breast Cancer Research Foundation
Elected to Phi Beta Kappa and Alpha Omega Alpha
Fellow, American Society of Clinical Oncology (FASCO)
Fellow, American Association for Cancer Research (FAACR)
Board Certified in Internal Medicine and Medical Oncology

Areas of Specialization

Breast cancer and hereditary cancers
Mathematical modeling of cancer growth and treatment optimization
Cancer metastasis research
Drug development in oncology
Cancer prevention, diagnosis, and treatment

Publications

2026

Oh JH, Zhu Y, Srivastava H, Deasy JO, et al. Abstract 5254: Copy Number Amplification of PSG is Associated with Poor Survival in Female Lung Adenocarcinoma Patients. Apr 2026.
Ferrando L, Dopeso H, Gusain L, Pareja F, et al. Abstract 5296: Epigenetic and Transcriptional Drivers of Mucinous Breast Carcinoma. Apr 2026.
Sareen N, Kulkarni A, Lake D, Singh J, et al. CLO26-115: Association Between Geriatric Assessment Variables and Treatment Completion in Older Adults With Triple-Negative Breast Cancer. Mar 2026.
Safonov A, Lee M, Brown DN, Razavi P, et al. Homologous Recombination Deficiency and Hemizygosity Drive Resistance in Breast Cancer. Mar 2026.
McArthur HL, Page DB, Rice S, Norton L, et al. Abstract PD7-07: Three-Year Event-Free Survival from a Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer. Feb 2026.
Schwartz CJ, Muldoon D, Dopeso H, Pareja FM, et al. Abstract PS4-03-18: Homologous Recombination Deficiency and DNA-Damage Response in Breast Invasive Lobular Carcinoma. Feb 2026.
Da Cruz Paula A, Muldoon D, Gazzo A, Pareja FM, et al. Abstract PS2-07-30: Structural Variants in Homologous Recombination Repair/DNA Damage Response Pathways as an Alternative Mechanism of Genomic Instability in Breast Cancer. Feb 2026.
Giridhar KV, Nenad WC, Ye H, Aurora US Metastases Network, et al. Abstract PS2-07-17: Characterizing Circulating Tumor Cell Enumeration and Phenotypic Profiling in Blood with Synchronously Obtained Tissue in Metastatic Breast Cancer. Feb 2026.
Cabel L, An JA, Kim HK, Razavi P, et al. Monitoring of Circulating Tumor DNA in Patients with Stage II-III Breast Cancer Treated with Neoadjuvant Chemotherapy. Jan 2026.

2025

Abuhadra N, Pareja F, White C, Montagna G, et al. Predictors of Response to Neoadjuvant Chemo-Immunotherapy in Metaplastic Triple-Negative Breast Cancer. Oct 2025.
Moiso E, Ferraro E, Safonov A, Razavi P, et al. 497P Multimodal Integration of Clinical, Genomic and Laboratory Data to Predict Outcomes on CDK4/6 Inhibitors in Patients with Metastatic Breast Cancer. Sep 2025.
Selenica P, Dopeso H, Repetto M, Pareja F, et al. Genomic Landscape of Breast Cancer in Elderly Patients. Jul 2025.
Oh JH, Pareja F, Elkin R, Deasy JO, et al. Abstract B033: Identifying Triple-Negative Breast Cancer Patients at High Risk of Worse Prognosis Using Molecular Features Derived from Histology Images. Jul 2025.
Moiso E, Ferraro E, Cabel L, Razavi P, et al. Abstract GS3-09: Multimodal Integration of Real World Clinical and Genomic Data for the Prediction of CDK4/6 Inhibitors Outcomes in Patients with HR+/HER2- Metastatic Breast Cancer. Jun 2025.
Pareja F, Da Cruz Paula A, Schwartz CJ, Weigelt B, et al. Abstract P1-05-17: Structural Variants Affecting CDH1 in Breast Invasive Lobular Carcinoma. Jun 2025.
Schwartz C, Oh JH, Rana S, Pareja F, et al. Abstract P1-03-24: Genomic and Clinicopathologic Profiling of Breast Invasive Lobular Carcinoma in Patients with Germline Predisposition. Jun 2025.
Kulkarni A, Lake D, White C, Singh J, et al. Abstract P2-11-22: Tolerance of Neoadjuvant Chemotherapy in Combination with Immunotherapy in Older Patients with Triple Negative Breast Carcinoma: The MSKCC Experience. Jun 2025.
An JA, Jasper J, Cabel L, Razavi P, et al. Ultrasensitive ctDNA Monitoring During CDK4/6 Inhibitor Therapy for Metastatic Breast Cancer. Jun 2025.
Sobarzo A, Msamra M, Elkin R, Kessous R, et al. Personalizing Breast Cancer Treatment with Patient-Derived Xenografts (PDX): Analyzing PDXs Fidelity, Stability, and Intra-Tumoral Heterogeneity. May 2025.
Oh JH, Rizzuto G, Elkin R, Deasy JO, et al. Pregnancy-Specific Glycoproteins as Potential Drug Targets for Female Lung Adenocarcinoma Patients. Apr 2025.
Oh JH, Rizzuto G, Elkin R, Deasy JO, et al. Abstract 2398: Pregnancy-Specific Glycoproteins in Tumors are Strong Predictors of Outcome in Female Lung Adenocarcinoma Patients. Apr 2025.
Tao JJ, Setton J, Sánchez Vela P, Khan AJ, et al. Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy. Apr 2025.
Simhal AK, Firestone RS, Oh JH, Deasy JO, et al. High WEE1 Expression is Independently Linked to Poor Survival in Multiple Myeloma. Feb 2025.
Oh JH, Pareja F, Elkin R, Deasy JO, et al. Biological Correlates Associated with High-Risk Breast Cancer Patients Identified Using a Computational Method. Jan 2025.
Metzger Filho O, Ballman KV, Campbell J, Symmans WF, et al. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. Jan 2025.

2024

Weistuch C, Murgas KA, Zhu J, Deasy JO, et al. Normal Tissue Transcriptional Signatures for Tumor-Type-Agnostic Phenotype Prediction. Nov 2024.
Simhal AK, Firestone RS, Oh JH, Deasy JO, et al. High WEE1 Expression Correlates with Poor Survival in Multiple Myeloma, Independent of Standard Prognostic Factors. Nov 2024.
Mai N, dos Anjos CH, Razavi P, Jhaveri K, et al. Predictors of Response to CDK4/6i Retrial after Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. Oct 2024.
Adewole T, Albrecht B, Beg S, Zhou Q, et al. Advancing Global Health Equity in Oncology Clinical Trial Access. Sep 2024.
Simhal AK, Firestone RS, Oh JH, Maclachlan K, et al. P-247: Increased WEE1 Expression is Predictive of Short Progression-Free Survival, Independent of Standard Prognostic Factors in Multiple Myeloma. Sep 2024.
Murciano-Goroff YR, Hui AB, Araujo-Filho J, Diehn M, et al. Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients with Small Cell Lung Cancer. Sep 2024.
Tai Y, Chow A, Han S, Acharyya S, et al. FLT1 Activation in Cancer Cells Promotes PARP-Inhibitor Resistance in Breast Cancer. Jul 2024.
Mai N, Myers S, Shen S, Abuhadra N, et al. Dose Dense Doxorubicin plus Cyclophosphamide in a Modified KEYNOTE522 Regimen for Triple Negative Breast Cancer. Jun 2024.
Sha C, Liu M, Goldberg J, Zhi I, et al. Immunotherapy Related Patient-Reported Outcomes from Five Randomized Controlled Trials in Patients with Triple Negative Breast Cancer: A Systematic Review. Jun 2024.
Moiso E, Ferraro E, Cabel L, Razavi P, et al. Predicting CDK4/6 Inhibitors Outcomes in Patients with HR+/HER2- Metastatic Breast Cancer: A Machine Learning Approach. Jun 2024.
Kim HK, An JA, Smith CG, Razavi P, et al. Personalized Circulating Tumor DNA for Minimal Residual Disease and Dynamic Assessment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer: Preliminary Analysis from MSK-LINC. Jun 2024.
Pareja F, Gazzo A, Dopeso H, Weigelt B, et al. Abstract PO3-14-08: Metaplastic Breast Cancer: Whole Genome Sequencing Analysis and Emerging Therapeutic Targets. May 2024.
McArthur HL, Comen E, Bryce Y, Norton L, et al. Abstract PO5-19-07: A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer. May 2024.
Singh J, Lake D, Dente-Ferguson W, Zhi WI, et al. Abstract PO1-03-06: Older Patients with Early Stage Triple Negative Breast Cancer: The Memorial Sloan Kettering Cancer Center Experience. May 2024.
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Winer EP, et al. 6th and 7th International Consensus Guidelines for the Management of Advanced Breast Cancer (ABC Guidelines 6 and 7). May 2024.
Aguirre-Ghiso J, Papanicolaou M, Sánchez Vela P, Levine R, et al. Abstract SY34-02: Age-Related and Organ-Specific Host Mosaicism as a Driver of Dormant Cancer Cell Awakening. Apr 2024.
Tracy B, Tarverdyan R, Li S, Bauml J, et al. The Evolution from Infrastructure as Code to Environment as Code. Feb 2024.
Comen E, Budhu S, Elhanati Y, McArthur HL, et al. Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer. Feb 2024.
Elkin R, Oh JH, Dela Cruz F, Tannenbaum A, et al. Dynamic Network Curvature Analysis of Gene Expression Reveals Novel Potential Therapeutic Targets in Sarcoma. Jan 2024.

2023

Sidorov M, Franke F, Dibaj S, Norton L, et al. Comparison Between Kubernetes Package Management Tool Kustomize and Helm. Dec 2023.
Simhal AK, Maclachlan KH, Elkin R, Tannenbaum A, et al. Gene Interaction Network Analysis in Multiple Myeloma Detects Complex Immune Dysregulation Associated with Shorter Survival. Nov 2023.
Simhal AK, Maclachlan KH, Usmani SZ, Tannenbaum A, et al. Network Modeling of Apoptosis-Related Genes Reveal a High-Risk Cluster in Multiple Myeloma. Nov 2023.
Taylor CW, Dodwell D, McGale P, Poortmans P, et al. Radiotherapy to Regional Nodes in Early Breast Cancer: An Individual Patient Data Meta-Analysis of 14,324 Women in 16 Trials. Nov 2023.
Zhu J, Veeraraghavan H, Jiang J, Tannenbaum A, et al. Wasserstein HOG: Local Directionality Extraction via Optimal Transport. Oct 2023.
Safonov A, Mehine M, Ceyhan-Birsoy O, Mandelker D, et al. 2231O Pan-Cancer Assessment of the Impact of Intronic Variants on Cancer Development and Progression. Oct 2023.
Grabenstetter A, Brogi E, Thompson DM, Wen HY, et al. Impact of Reactive Changes on Multigene Testing: Histopathologic Analysis of Low-Grade Breast Cancers with High-Risk 21-Gene Recurrence Scores. Sep 2023.
Franch-Expósito S, Mehine M, Ptashkin RN, Zehir A, et al. Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients with Solid Tumors. Aug 2023.
Shen S, Solomon V, Williams D, Iyengar N, et al. The ARETHA Study: A Phase 2 Randomized Control Trial of Eribulin with Evexomostat (SDX-7320) or Placebo for Patients with Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction. Jun 2023.
Zhi I, Lake DE, Ehrich F, Singh JC, et al. Older Patients with Early-Stage Triple-Negative Breast Cancer: The Memorial Sloan Kettering Cancer Center Experience. Jun 2023.
Abuhadra N, Chen Y, Plitas G, Montagna G, et al. Prospective Evaluation of Pathologic Response with Neoadjuvant Chemo-Immunotherapy in Metaplastic Breast Cancer. Jun 2023.
McArthur HL, Comen EA, Bryce Y, Norton L, et al. A Single-Arm Phase 2 Study of Peri-Operative Checkpoint-Mediated Immune Therapy and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative, Early-Stage/Resectable Breast Cancer. Jun 2023.
Zhu J, Oh JH, Simhal AK, Tannenbaum A, et al. Geometric Graph Neural Networks on Multi-Omics Data to Predict Cancer Survival Outcomes. Jun 2023.
Caballero C, Irrthum A, Goulioti T, Piccart M, et al. International Research to Address the Challenges of Metastatic Breast Cancer: The AURORA Program (BIG 14-01). May 2023.
Abou-Alfa GK, Norton L, Alvarez-Gómez RM, et al. Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management. Feb 2023.
Belkhatir Z, Berkane S, Norton L, Tannenbaum A. Nonlinear Impulsive Control Design for Biologically Grounded NSM Tumor Growth Model Using Exact Linearized Mapping. Jan 2023.

2022

García-Recio S, Hinoue T, Wheeler G, Perou CM, et al. Multiomics in Primary and Metastatic Breast Tumors from the AURORA US Network Finds Microenvironment and Epigenetic Drivers of Metastasis. Dec 2022.
Fraenkel M, Novack V, Mizrakli Y, Geffen D, et al. Bone Mineral Density in Women Newly Diagnosed with Breast Cancer: A Prospective Cohort Study. Dec 2022.
Simhal AK, Maclachlan KH, Elkin R, Tannenbaum A, et al. Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma. Nov 2022.
Ginsberg SD, Sharma S, Norton L, Chiosis G, et al. Targeting Stressor-Induced Dysfunctions in Protein-Protein Interaction Networks via Epichaperomes. Nov 2022.
Grabenstetter A, Brogi E, Zhang H, Wen HY, et al. Solid-Basaloid Variant of Adenoid Cystic Carcinoma of the Breast with Near Complete Response to Neoadjuvant Chemotherapy. Aug 2022.
Safonov A, Bandlamudi C, Selenica P, Razavi P, et al. Allelic Dosage of RB1 Drives CDK4/6 Inhibitor Treatment Resistance in Metastatic Breast Cancer. Jun 2022.
Tao J, Setton J, Sanchez Vela P, Razavi P, et al. Impact of Clonal Hematopoiesis on Tumor Control Following Radiation Therapy. Jun 2022.
McArthur HL, Comen EA, Bryce Y, Norton L, et al. A Single-Arm, Phase 2 Study of Perioperative Ipilimumab, Nivolumab, and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative, Early-Stage/Resectable Breast Cancer. Jun 2022.
Zhu J, Veeraraghavan H, Norton L, Tannenbaum A, et al. Wasserstein Image Local Analysis: Histogram of Orientations, Smoothing and Edge Detection. May 2022.
Page DB, Beal K, Linch S, McArthur HL, et al. Brain Radiotherapy, Tremelimumab-Mediated CTLA-4-Directed Blockade +/- Trastuzumab in Patients with Breast Cancer Brain Metastases. Apr 2022.
Ferraro E, Singh J, Patil S, Dang C, et al. Incidence of Brain Metastases in Patients with Early HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy with Trastuzumab and Pertuzumab. Mar 2022.
Zhi WI, Mao JJ, Baser RE, Bao T, et al. Abstract P4-08-01: Effectiveness of Electroacupuncture versus Auricular Acupuncture in Breast Cancer Survivors with Chronic Musculoskeletal Pain: The PEACE Randomized Clinical Trial. Feb 2022.
Ferraro E, Smith A, Safonov A, Razavi P, et al. Abstract GS3-03: Genomic Analysis of 733 HER2+ Breast Cancers Identifies Recurrent Pathways Alterations Associated with Anti-HER2 Resistance and New Therapeutic Vulnerabilities. Feb 2022.
Safonov A, Bandlamudi C, Tallón de Lara P, Razavi P, et al. Abstract GS4-08: Comprehensive Genomic Profiling of Patients with Breast Cancer Identifies Germline-Somatic Interactions Mediating Therapy Resistance. Feb 2022.

2021

Trastuzumab for Early-Stage, HER2-Positive Breast Cancer: A Meta-Analysis of 13,864 Women in Seven Randomised Trials. (EBCTCG collaboration) Aug 2021.
Kumar R, Hortobagy GN, Albanell J, Norton L, et al. In Memoriam: José Baselga’s Journey in Cancer Medicine. Jun 2021.
Taghvaei A, Georgiou T, Norton L, Tannenbaum A. Fractional SIR Epidemiological Models. Nov 2020.

2020

Piccart MJ, Hilbers F, Bliss JM, Winer EP, et al. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Oct 2020.
Cardoso F, Paluch-Shimon S, Senkus-Konefka E, Winer EP, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Sep 2020.
Belkhatir Z, Pavon M, Mathews JC, Tannenbaum AR, Norton L, et al. Stochastic Norton-Simon-Massagué Tumor Growth Modeling: Controlled and Mixed-Effect Uncontrolled Analysis. Mar 2020.
Norton L, Kirk R. Supporting Data Sharing. Dec 2019.

2019

Tannenbaum A, Georgiou T, Deasy JO, Norton L. Control and the Analysis of Cancer Growth Models. Apr 2019.
Scott JM, Dolan LB, Norton L, Jones LW, et al. Multisystem Toxicity in Cancer: Lessons from NASA’s Countermeasures Program. Nov 2019.
McArthur HL, Comen EA, Bryce Y, Norton L, et al. 288TiP A Randomized Phase II Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation versus Standard Care in Women with Residual, Early Stage/Resectable, Triple Negative Breast Cancer after Standard-of-Care Neoadjuvant Chemotherapy. Oct 2019.
Kumar R, Van de Vijver M, Tortora G, Norton L, et al. A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. Sep 2019.
Gray R, Bradley R, Braybrooke J, Norton L, et al. Increasing the Dose Intensity of Chemotherapy by More Frequent Administration or Sequential Scheduling: A Patient-Level Meta-Analysis of 37,298 Women with Early Breast Cancer in 26 Randomised Trials. Feb 2019.
Vasileva D, Norton L, Hurlbert M, Lo AW. Measuring the Economic and Academic Impact of Philanthropic Funding: The Breast Cancer Research Foundation. Jan 2019.

2018

Komura K, Yoshikawa Y, Shimamura T, Kantoff PW, Norton L, et al. ATR Inhibition Controls Aggressive Prostate Tumors Deficient in Y-Linked Histone Demethylase KDM5D. J Clin Invest, Jul 2018.
Gray R, Bradley R, Braybrooke J, Norton L, et al. Abstract GS1-01: Increasing the Dose Density of Adjuvant Chemotherapy by Shortening Intervals between Courses or by Sequential Drug Administration Significantly Reduces Both Disease Recurrence and Breast Cancer Mortality. Feb 2018.
Tannenbaum A, Georgiou T, Deasy JO, Norton L. Control and the Analysis of Cancer Growth Models. Jan 2018.

2017

Norton L. Dealing with the Tyranny of Certainty in the (Medical) Digital Age. Feb 2017.
Traina TA, Norton L. Norton-Simon Hypothesis. Chapter, Jan 2017.
Traina TA, Norton L. Log-Kill Hypothesis. Chapter, Jan 2017.
Norton L. Tumor Growth Kinetics. Chapter, Feb 2017. (with Comen E, Gilewski TA)
Cardoso F, Costa A, Senkus-Konefka E, Winer EP, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Feb 2017.
Gray R, Bradley R, Braybrooke J, Norton L, et al. Abstract P5-14-04: Effects of Dose-Dense Chemotherapy on Recurrence and Cause-Specific Mortality in Women with Early Breast Cancer. Feb 2017.

2016

McArthur HL, Diab A, Page DB, Norton L, et al. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Nov 2016.

2015

Norton L. Current Management of Lesions Associated with an Increased Risk of Breast Cancer. Jan 2015. (with Morrow M, Schnitt SJ)
Norton L. Cell-to-Cell Communication in Cancer: Workshop Report. Nov 2015. (with Oktay MH, Lee YF, Harney A)

2014

Norton L. Cancer Log-Kill Revisited. May 2014.
Gucalp A, Gupta GP, Pilewskie M, Norton L, et al. Advances in Managing Breast Cancer: A Clinical Update. Aug 2014.
Cardoso F, Costa A, Norton L, Winer EP, et al. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Sep 2014.

2012

Norton L. The Mathematics of Tumor Growth and Treatment. Conference Paper, Feb 2012.

2010

Slamon DJ, Leyland-Jones B, Shak S, Norton L, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med, Apr 2001. (landmark paper)

2009–2006

Simon R, Norton L. The Norton-Simon Hypothesis: Designing More Effective and Less Toxic Chemotherapeutic Regimens. Sep 2006.
Norton L, Hudis C. Role of Modeling in Pharmacotherapeutics. Jan 2006.
Norton L. The Concept of Mathematically Optimised Dose-Scheduling as Applied to the Adjuvant Chemotherapy of Primary Breast Cancer. Jan 2008.

2004–2000

Norton L. Kinetic Concepts in the Systemic Drug Therapy of Breast Cancer. Mar 1999.
Norton L. Adjuvant Breast Cancer Therapy: Current Status and Future Strategies — Growth Kinetics and the Improved Drug Therapy of Breast Cancer. Mar 1999.
Hudis C, Seidman A, Baselga J, Norton L, et al. Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy. Jan 1999.
Seidman A, Hudis C, Norton L, et al. Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer with Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification. Jun

2001.

Gilewski T, Ragupathi G, Bhuta S, Norton L, Livingston PO, et al. Immunization of Metastatic Breast Cancer Patients with a Fully Synthetic Globo H Conjugate: A Phase I Trial. Apr 2001.

Pre-2000 — Landmark Papers

Norton L, Simon R. Tumor Size, Sensitivity to Therapy, and Design of Treatment Schedules. Cancer Treat Rep, Nov 1977.
Norton L, Simon R, Brereton HD, Bogden AE. Predicting the Course of Gompertzian Growth. Jan 1977.
Norton L, Simon R. Growth Curve of an Experimental Solid Tumor Following Radiotherapy. Jul 1977.
Norton L, Simon R. The Norton-Simon Hypothesis Revisited. Feb 1986.
Citron ML, Berry DA, Cirrincione C, Norton L, et al. Superiority of Dose-Dense over Conventional Scheduling and Equivalence of Sequential vs. Combination Adjuvant Chemotherapy for Node-Positive Breast Cancer (CALGB 9741). 2003.
Baselga J, Tripathy D, Mendelsohn J, Norton L, et al. Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer. Apr 1996.
Seidman A, Hudis C, Albany J, Norton L, et al. Dose-Dense Therapy with Weekly 1-Hour Paclitaxel Infusions in the Treatment of Metastatic Breast Cancer. Oct 1998.
Norton L. A Gompertzian Model of Human Breast Cancer Growth. Cancer Res, 1988.
Wood WC, Budman DR, Korzun AH, Norton L, et al. Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. May 1994.
Baselga J, Norton L, Albanell J, Mendelsohn J, et al. Recombinant Humanized Anti-HER2 Antibody Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts. Aug 1998.

All information is sourced from publicly available materials.

Larry Norton